Armando Salinas

Dr. Armando Salinas

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Neuron
Verified
Journal Article
Closed access
KAKarina P. Abrahao
Karina P. Abrahao
ASArmando Salinas
Armando Salinas
DLDavid M. Lovinger
David M. Lovinger

1 September 2016 in Neuropharmacology
Verified
Journal Article
Closed access
ASArmando Salinas
Armando Salinas
MDMargaret I. Davis
Margaret I. Davis
DLDavid M. Lovinger
David M. Lovinger
YMYolanda Mateo
Yolanda Mateo

22 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASArmando Salinas
Armando Salinas
JLJeong Oen Lee
Jeong Oen Lee
SAShana M. Augustin
Shana M. Augustin
SZShiliang Zhang
Shiliang Zhang
TPTommaso Patriarchi
Tommaso Patriarchi
DLDavid M. Lovinger
David M. Lovinger
The development of genetically encoded dopamine sensors such as dLight has provided a new approach to measuring slow and fast dopamine dynamics both in brain slices and in vivo, possibly enabling dopamine measurements in areas like the dorsolateral striatum (DLS) where previously such recordings with fast-scan cyclic voltammetry (FSCV) were difficult. To test this, we first evaluated dLight photometry in mouse brain slices with simultaneous FSCV and found that both techniques yielded comparable results, but notable differences in responses to dopamine transporter inhibitors, including cocaine. We then used in vivo fiber photometry with dLight in mice to examine responses to cocaine in DLS. We also compared dopamine responses during Pavlovian conditioning across the striatum. We show that dopamine increases were readily detectable in DLS and describe transient dopamine kinetics, as well as slowly developing signals during conditioning. Overall, our findings indicate that dLight photometry is well suited to measuring dopamine dynamics in DLS.

1 April 2007 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
AHAdam W. Hendricson
Adam W. Hendricson
RMRegina E. Maldve
Regina E. Maldve
ASArmando Salinas
Armando Salinas
JTJonathan W. Theile
Jonathan W. Theile
TZTao A. Zhang
Tao A. Zhang
RMRichard A. Morrisett
Richard A. Morrisett
Chronic ethanol exposure may induce neuroadaptive responses in N-methyl-d-aspartate (NMDA) receptors, which are thought to underlie a variety of alcohol-related brain disorders. Here, we demonstrate that hyperexcitability triggered by withdrawal from chronic ethanol exposure is associated with increases in both synaptic NMDA receptor expression and activation. Withdrawal from chronic ethanol exposure (75 mM ethanol, 5–9 days) elicited robust and prolonged epileptiform activity in CA1 pyramidal neurons from hippocampal explants, which was absolutely dependent upon NMDA receptor activation but independent of chronic inhibition of protein kinase A (PKA). Analysis of Sr2+-supported asynchronous NMDA receptor-mediated miniature excitatory postsynaptic currents (mEPSCs) was employed to assess changes in NMDA neurotransmission. After chronic exposure, ethanol withdrawal was associated with an increase in mEPSC amplitude 3.38-fold over that after withdrawal from acute ethanol exposure. Analysis of paired evoked α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid EPSCs and spontaneous mEPSCs indicated that withdrawal after chronic exposure was also associated with a selective increase in action potential evoked but not spontaneous transmitter release probability. Immunoblot analysis revealed significant increases in total NR1, NR2A, and NR2B subunit expression after chronic exposure and unaffected by PKA-inhibition manner. Confocal imaging studies indicate that increased NR1 subunit expression was associated with increased density of NR1 expression on dendrites in parallel with a selective increase in the size of NR1 puncta on dendritic spines. Therefore, neuroadaptation to chronic ethanol exposure in NMDA synaptic transmission is responsible for aberrant network excitability after withdrawal and results from changes in both postsynaptic function as well as presynaptic release.

17 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZLZhenhua Liu
Zhenhua Liu
NYNannan Yang
Nannan Yang
JDJie Dong
Jie Dong
WTWotu Tian
Wotu Tian
LCLisa Chang
Lisa Chang
BTBeisha Tang
Beisha Tang
Endocannabinoid (eCB),2-arachidonoyl-glycerol (2-AG), the most abundant eCB in the brain, regulates diverse neural functions. Here we linked multiple homozygous loss-of-function mutations in 2-AG synthase diacylglycerol lipase β (DAGLB) to an early onset autosomal recessive Parkinsonism. DAGLB is the main 2-AG synthase in human and mousesubstantia nigra(SN) dopaminergic neurons (DANs). In mice, the SN 2-AG levels were markedly correlated with motor performance during locomotor skill acquisition. Genetic knockdown ofDaglbin nigral DANs substantially reduced SN 2-AG levels and impaired locomotor skill learning, particularly the across-session learning. Conversely, pharmacological inhibition of 2-AG degradation increased nigral 2-AG levels, DAN activity and dopamine release and rescued the locomotor skill learning deficits. Together, we demonstrate thatDAGLB-deficiency contributes to the pathogenesis of Parkinsonism, reveal the importance of DAGLB-mediated 2-AG biosynthesis in nigral DANs in regulating neuronal activity and dopamine release, and suggest potential benefits of 2-AG augmentation in alleviating Parkinsonism.

13 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CSCarmelo Sgobio
Carmelo Sgobio
JWJunbing Wu
Junbing Wu
WZWang Zheng
Wang Zheng
XCXi Chen
Xi Chen
JPJing Pan
Jing Pan
HCHuaibin Cai
Huaibin Cai
Aldehyde dehydrogenase 1 (ALDH1A1)–positive dopaminergic (DA) neurons at the ventral substantia nigra pars compacta (SNpc) preferentially degenerate in Parkinson’s disease (PD). Their projection pattern and dopamine release properties, however, remains uncharacterized. Here we show that ALDH1A1–positive axons project predominantly to the rostral two–thirds of dorsal striatum. A portion of these axons converge on a small fraction of striosome compartments restricted to the dorsolateral striatum (DLS), where less dopamine release was measured compared to the adjacent matrix enriched with the ALDH1A1–negative axons. Genetic ablation of Aldh1a1 substantially increases the dopamine release in striosomes, but not in matrix. Additionally, the presence of PD-related human α-synuclein A53T mutant or dopamine transporter (DAT) blockers also differentially affects the dopamine output in striosomes and matrix. Together, these results demonstrate distinct dopamine release characteristics of ALDH1A1–positive DA fibers, supporting a regional specific function of ALDH1A1 in regulating dopamine availability/release in striatum.